112 related articles for article (PubMed ID: 3437788)
1. Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl J; Reissmann T; Voegeli R
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
[TBL] [Abstract][Full Text] [Related]
2. Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression.
Reissmann T; Hilgard P; Voegeli R; Zeller J
J Cancer Res Clin Oncol; 1989; 115(6):525-30. PubMed ID: 2606928
[TBL] [Abstract][Full Text] [Related]
3. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.
Schomburg A; Menzel T; Hadam M; Duensing S; Körfer A; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Jun; 4(2):58-65. PubMed ID: 1515095
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
Reissmann T; Voegeli R; Pohl J; Hilgard P
Cancer Immunol Immunother; 1989; 28(3):179-84. PubMed ID: 2924329
[TBL] [Abstract][Full Text] [Related]
5. Elimination of immune suppressor mechanisms in humans by oxazaphosphorines.
Berd D; Mastrangelo MJ
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):569-77. PubMed ID: 2963936
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and early clinical trial with mafosfamide as immune modulator.
Klein HO; Kreysch HG; Coerper C; Voigt P; Ruff I
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):627-40. PubMed ID: 3325719
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
8. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide.
Davidoff AN; Mendelow BV
Exp Hematol; 1993 Jul; 21(7):922-7. PubMed ID: 8319782
[TBL] [Abstract][Full Text] [Related]
9. Modulation of IL-10/IL-10R expression by mafosfamide, a derivative of 4-hydroxycyclophosphamide, in a rat B-cell lymphoma.
Rico MJ; Matar P; Scharovsky OG
Biocell; 2012 Aug; 36(2):91-5. PubMed ID: 23185784
[TBL] [Abstract][Full Text] [Related]
10. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K
Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets.
Botzler C; Kis K; Issels R; Multhoff G
Exp Hematol; 1997 Apr; 25(4):338-44. PubMed ID: 9131009
[TBL] [Abstract][Full Text] [Related]
12. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.
Sreerama L; Sladek NE
Cancer Res; 1994 Apr; 54(8):2176-85. PubMed ID: 8174125
[TBL] [Abstract][Full Text] [Related]
13. High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines.
Fritz G; Hengstler JG; Kaina B
Cancer Res; 1997 Feb; 57(3):454-60. PubMed ID: 9012473
[TBL] [Abstract][Full Text] [Related]
14. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
15. Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture.
Brock N
Cancer Res; 1989 Jan; 49(1):1-7. PubMed ID: 2491747
[TBL] [Abstract][Full Text] [Related]
16. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
18. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
[TBL] [Abstract][Full Text] [Related]
19. [Enhancement of the antitumor transplantation resistance in rats by the antileukemia drug busulfan (author's transl)].
Mizushima Y
Hokkaido Igaku Zasshi; 1980 Nov; 55(6):537-42. PubMed ID: 7274985
[TBL] [Abstract][Full Text] [Related]
20. [Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide (author's transl)].
Terashima M
Hokkaido Igaku Zasshi; 1980 Nov; 55(6):495-9. PubMed ID: 6456215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
